Aylı Meltem, Özcan Muhit, Cengiz Seval Güldane
Ufuk University Faculty of Medicine, Department of Hematology, Ankara, Turkey E-mail:
Turk J Haematol. 2015 Jun;32(2):180-3. doi: 10.4274/tjh.2013.0338.
A 67-year-old male patient who was diagnosed with primary myelofibrosis 4 years ago did not respond to conventional therapies. The splenomegaly progressively increased, which caused spleen infarctions and led to the decision to perform a splenectomy procedure. After splenectomy, the patient started treatment with ruxolitinib. In the first month of ruxolitinib treatment, the patient became transfusion-free and all constitutional symptoms disappeared. However, in the sixth month of ruxolitinib treatment, the disease transformed to acute myeloblastic leukemia, and the patient died 1 month later. This is the first case report that shows the effects of ruxolitinib in a splenectomized patient.
一名67岁男性患者，4年前被诊断为原发性骨髓纤维化，对传统治疗无反应。脾肿大逐渐加重，导致脾梗死，因此决定进行脾切除术。脾切除术后，患者开始使用鲁索替尼治疗。在鲁索替尼治疗的第一个月，患者不再需要输血，所有全身症状均消失。然而，在鲁索替尼治疗的第六个月，疾病转变为急性髓细胞白血病，患者1个月后死亡。这是首例显示鲁索替尼对脾切除患者疗效的病例报告。
